ES2657226T3 - Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo - Google Patents

Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo Download PDF

Info

Publication number
ES2657226T3
ES2657226T3 ES10811290.5T ES10811290T ES2657226T3 ES 2657226 T3 ES2657226 T3 ES 2657226T3 ES 10811290 T ES10811290 T ES 10811290T ES 2657226 T3 ES2657226 T3 ES 2657226T3
Authority
ES
Spain
Prior art keywords
antibody
seq
pharmaceutical composition
monoclonal antibody
vegf monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10811290.5T
Other languages
English (en)
Inventor
Pierre Li
Yaohuang Ke
Yongke Zhang
Weimin Zhu
Guoliang Yu
Fanxin Ma
Xin FAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Apexigen Inc
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Apexigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd, Apexigen Inc filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2657226T3 publication Critical patent/ES2657226T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Un anticuerpo monoclonal que se une específicamente a VEGF, caracterizado porque el dominio variable de su cadena pesada comprende secuencias de aminoácidos de CDR 1-3 que consisten respectivamente en la SEQ ID NO. 1, SEQ ID NO. 2 y SEQ ID NO. 3, y el dominio variable de su cadena ligera comprende secuencias de aminoácidos de CDR 1-3 que consisten respectivamente en SEQ ID NO. 4, SEQ ID NO. 5 y SEQ ID NO. 6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10811290.5T 2009-08-28 2010-08-27 Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo Active ES2657226T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009101715509A CN102002104A (zh) 2009-08-28 2009-08-28 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN200910171550 2009-08-28
PCT/CN2010/076420 WO2011023130A1 (zh) 2009-08-28 2010-08-27 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Publications (1)

Publication Number Publication Date
ES2657226T3 true ES2657226T3 (es) 2018-03-02

Family

ID=43627282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10811290.5T Active ES2657226T3 (es) 2009-08-28 2010-08-27 Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo

Country Status (6)

Country Link
US (1) US8986692B2 (es)
EP (1) EP2471814B1 (es)
JP (1) JP5738294B2 (es)
CN (2) CN102002104A (es)
ES (1) ES2657226T3 (es)
WO (1) WO2011023130A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103992405B (zh) * 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN102875676B (zh) * 2011-07-13 2014-11-05 无锡天演生物技术有限公司 全人源抗人vegf单抗分子及其应用
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016109943A1 (zh) * 2015-01-06 2016-07-14 珠海亿胜生物制药有限公司 抗vegf抗体
WO2016159652A1 (ko) 2015-03-31 2016-10-06 일동제약주식회사 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물
KR102128966B1 (ko) 2015-09-01 2020-07-01 일동제약(주) 종양 투과성 펩타이드와 항-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물
US20190352386A1 (en) * 2015-09-14 2019-11-21 Galaxy Biotech, Llc Highly potent monoclonal antibodies to angiogenic factors
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
US11008387B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. Antibody inhibiting binding of VEGF to NRP1
EP3401331B1 (en) 2016-01-06 2022-04-06 Order-Made Medical Research Inc. High-affinity anti-vegf antibody
CN107537036A (zh) * 2016-06-27 2018-01-05 江苏泰康生物医药有限公司 一种抗人血管内皮生长因子单克隆抗体的药物制剂及其应用
CN110003328B (zh) * 2018-01-05 2022-04-19 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
CN114008075A (zh) * 2019-07-19 2022-02-01 神州细胞工程有限公司 人源化抗vegf单克隆抗体
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
JP2024506664A (ja) * 2021-02-10 2024-02-14 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ｖｅｇｆ抗体およびその使用
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用
CN116003619B (zh) * 2022-12-12 2023-08-04 三门峡市眼科医院 人源化抗Ang-2和VEGF双功能抗体及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6342221B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US20040067496A1 (en) 2002-10-07 2004-04-08 Robert Pytela System for production and screening of monoclonal antibodies
US8071322B2 (en) 2002-11-12 2011-12-06 Epitomics, Inc. Method for identifying differentially expressed proteins
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
WO2005007671A2 (en) 2003-04-29 2005-01-27 Epitomics, Inc. Compositions and methods for treating sars
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US20050287118A1 (en) 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
CN101148474B (zh) 2006-09-21 2014-06-11 上海杰隆生物工程股份有限公司 人源人血管内皮生长因子单克隆抗体及其制备方法
MX2009004027A (es) * 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
CN103992405B (zh) 2008-03-26 2016-08-17 宜康公司 抗-vegf抗体
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CN101487005A (zh) * 2008-09-04 2009-07-22 林植华 人血管内皮生长因子单克隆抗体的基因及其应用
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
EP2681243B1 (en) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
CN110066335B (zh) 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法

Also Published As

Publication number Publication date
EP2471814A4 (en) 2013-04-03
US20120231011A1 (en) 2012-09-13
CN102448987A (zh) 2012-05-09
EP2471814B1 (en) 2018-01-03
JP5738294B2 (ja) 2015-06-24
WO2011023130A1 (zh) 2011-03-03
CN102448987B (zh) 2014-06-04
CN102002104A (zh) 2011-04-06
EP2471814A1 (en) 2012-07-04
US8986692B2 (en) 2015-03-24
JP2013502445A (ja) 2013-01-24

Similar Documents

Publication Publication Date Title
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
PE20171512A1 (es) Anticuerpos anti-fap
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
ES2684475T3 (es) Proteínas que se unen a beta amiloide
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
RS52775B (en) CD19 OPTIMIZED ANTIBODY
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
ES2664972T3 (es) Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
AR083747A1 (es) Anticuerpos anti-il-23
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
AR069775A1 (es) Anticuerpos bivalentes biespecificos
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201790757A1 (ru) Связывающие антиген cd27l белки